TOVX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TO

Volume

217.25K

Next Earnings

November 11th

Loading chart

TO

TOVXTheriva Biologics, Inc.

TOVX

Pay with—

Available Balance0.00

TO

Mkt Cap

$9.7M

Volume

217.25K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásicoTheriva Biologics announced the publication of Phase 2b VIRAGE trial results in Nature Medicine, showing that VCN-01 (zabilugene almadenorepvec) combined with standard chemotherapy improved overall survival, progression-free survival, and response duration in metastatic pancreatic cancer patients compared to chemotherapy alone. The company is now conducting the VIRAGE2 Phase 2a trial to evaluate more frequent dosing of VCN-01, with initial data expected in Q3 2027. VCN-01 has received orphan drug and rare pediatric disease designations.GlobeNewswire Inc. · Oct 1, 2026

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchTheriva Biologics reported Phase 1 trial results for VCN-01, an oncolytic adenovirus combined with durvalumab, in immunotherapy-refractory head and neck squamous cell carcinoma patients. The study demonstrated prolonged overall survival (15.5-17.3 months depending on dosing arm) and biomarker evidence supporting VCN-01's stroma-degrading and immune-enhancing mechanisms. Results were published in Clinical Cancer Research journal.GlobeNewswire Inc. · Jun 11, 2026

Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026Theriva Biologics announced upcoming presentation of additional data from the VIRAGE Phase 2b clinical trial of VCN-01 at the AACR 2026 Annual Meeting. The tumor response, biomarker, and subgroup analyses support an immune-mediated mechanism of action and demonstrate improved patient outcomes, including in patients with hepatic metastases. The company has reached agreement with FDA and EMA on a Phase 3 pivotal trial design for VCN-01 combined with gemcitabina/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer.GlobeNewswire Inc. · Apr 18, 2026

$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning MomentumSmall- and mid-cap stocks are gaining momentum on execution milestones and transformative deals. Interactive Strength surged 40% after acquiring Ergatta to boost revenue guidance by 50%. Kraig Biocraft Laboratories activated its 2026 production program for spider silk manufacturing. Theriva Biologics out-licensed an asset to focus on its pancreatic cancer program, while PMGC Holdings' subsidiary filed patents for animal health applications.GlobeNewswire Inc. · Feb 19, 2026

Theriva™ Biologics anuncia la próxima presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en el Congreso de la Academia de Oftalmología de Asia-Pacífico (APAO) de 2026Theriva Biologics announced that clinical and safety results from a Phase 1 study of VCN-01 (zabilugene almadenorepvec) for refractory retinoblastoma will be presented at the 41st Asia-Pacific Academy of Ophthalmology Congress in Hong Kong on February 7, 2026. The presentation will include preclinical data demonstrating synergistic antitumor activity when combining topotecan with VCN-01, potentially improving outcomes for patients with difficult-to-treat vitreous seeding.GlobeNewswire Inc. · Feb 3, 2026

Theriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásicoTheriva Biologics received favorable scientific advice from the European Medicines Agency (EMA) on the design of a Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC). The EMA approved the proposed trial design, sample size, and adaptive design elements. The company plans to meet with the FDA in H1 2026 for a multinational Phase 3 trial and has cash runway through Q1 2027.GlobeNewswire Inc. · Dec 29, 2025

Theriva Biologics Provides Response to Unusual Market ActionTheriva Biologics reported unusual trading activity in its stock on October 24, 2025, and stated there are no material undisclosed developments causing the market action. The company is developing cancer therapeutics and has recently presented expanded data from its VIRAGE trial at ESMO 2025.GlobeNewswire Inc. · Oct 24, 2025

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial ResultsTheriva Biologics announced positive Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer, with improved overall survival and progression-free survival. The company is preparing for a potential Phase 3 trial and presented retinoblastoma study data at ASCO 2025.GlobeNewswire Inc. · Aug 11, 2025

US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says AnalystUS stock futures are trading higher ahead of a shortened trading session on Christmas Eve. Analysts expect a 'Santa Rally' during this period, which has historically seen positive returns. However, they also caution about potential market corrections in 2025 due to stretched valuations.Benzinga · Dec 24, 2024

Theriva™ Biologics anuncia la orientación de la FDA estadounidense con respecto al diseño del estudio de Fase 3 del VCN-01 para el tratamiento del cáncer de páncreas metastásicoTheriva Biologics announced that the FDA provided guidance on the design of a Phase 3 study for their lead candidate VCN-01 in combination with standard chemotherapy for the treatment of metastatic pancreatic cancer. The FDA recommended conducting an independent Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel, rather than expanding the ongoing Phase 2b VIRAGE study.GlobeNewswire Inc. · Dec 5, 2024

to start trading

TO

TOVXTheriva Biologics, Inc.

TOVX

Pay with—

Available Balance0.00

Your PositionYou don't own any TOVX yet.

Related Tickers

Earnings